Terns Pharmaceuticals Inc [TERN] stock prices are up 2.49% to $8.23 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TERN shares have gain 7.72% over the last week, with a monthly amount glided 16.57%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Terns Pharmaceuticals Inc [NASDAQ: TERN] stock has seen the most recent analyst activity on September 17, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $15. On February 28, 2025, William Blair initiated with a Mkt Perform rating. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $82 on October 31, 2024. Mizuho initiated its recommendation with a Buy and recommended $16 as its price target on June 22, 2023. Jefferies started tracking with a Buy rating for this stock on June 07, 2023, and assigned it a price target of $18. In a note dated May 31, 2023, ROTH MKM initiated an Buy rating and provided a target price of $23 on this stock.
The stock price of Terns Pharmaceuticals Inc [TERN] has been fluctuating between $1.87 and $8.46 over the past year. Currently, Wall Street analysts expect the stock to reach $15 within the next 12 months. Terns Pharmaceuticals Inc [NASDAQ: TERN] shares were valued at $8.23 at the most recent close of the market. An investor can expect a potential return of 82.26% based on the average TERN price forecast.
Analyzing the TERN fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.27 and Total Capital is -0.34. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.05 points at the first support level, and at 7.88 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.36, and for the 2nd resistance point, it is at 8.50.
Ratios To Look Out For
It’s worth pointing out that Terns Pharmaceuticals Inc [NASDAQ:TERN]’s Current Ratio is 24.70. In addition, the Quick Ratio stands at 24.70 and the Cash Ratio stands at 11.3.
Transactions by insiders
Recent insider trading involved Kuriakose Emil, Chief Medical Officer, that happened on Oct 01 ’25 when 944.0 shares were sold. Chief Medical Officer, Kuriakose Emil completed a deal on Jul 01 ’25 to sell 853.0 shares. Meanwhile, Chief Financial Officer Gengos Andrew bought 10000.0 shares on Jun 27 ’25.
